Edwige Abeilard
Caen, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
UPR/ATF4/Noxa pathway overactivation through SERCA2 inhibition or ONC201 treatment combined with ABT-737 triggers apoptosis in chemoresistant ovarian cancer cells and patient-derived tumor organoids.
Journal: Cell death & disease
Published: May 28, 2025
LncRNA MYO16-AS1 and MICAL2 axis sustains proliferation and migration in ovarian cancer cells and unveils a therapeutic vulnerability in patient-derived tumor organoids.
Journal: Non-coding RNA research
Published: March 10, 2025
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
Journal: Journal of experimental & clinical cancer research : CR
Published: March 03, 2023
Network-Based Integration of Multi-Omics Data Identifies the Determinants of miR-491-5p Effects.
Journal: Cancers
Published: June 23, 2021
The lncRNA 'UCA1' modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels.
Journal: Molecular oncology
Published: November 30, 2020
Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib.
Journal: Cell death & disease
Published: December 02, 2019
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids.
Journal: Molecular cancer therapeutics
Published: May 14, 2019
Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BclxL strategies through Mcl-1 down-regulation.
Journal: Oncotarget
Published: October 27, 2017
The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Journal: Molecular cancer therapeutics
Published: May 25, 2016
Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.
Journal: Apoptosis : an international journal on programmed cell death
Published: January 29, 2015
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Journal: International journal of cancer
Published: March 06, 2014
Last Updated: 09/26/2026